Sandbox Reserved 1337
From Proteopedia
(Difference between revisions)
| Line 23: | Line 23: | ||
== References == | == References == | ||
<references/> | <references/> | ||
| - | Ferrara N. Vascular Endothelial Growth Factor. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29(6): http://atvb.ahajournals.org/content/29/6/789.full. Accessed October 19, 2017. | ||
| - | Markovic-Mueller S, Stuttfeld E, Asthana M, Weinert T, Bliven S, Goldie K, Kisko K, Capitani G, Ballmer-Hofer K. Structure of the Full-length VEGFR-1 Extracellular Domain in Complex with VEGF-A. 2017; 25(2): 341-352. http://www.sciencedirect.com/science/article/pii/S0969212616304026. Accessed October 19, 2017. | ||
| - | Klamerus JF, Brahmer JR. Optimizing the Dose and Schedule of Anti–Vascular Endothelial Growth Factor Antibodies in Non–Small-Cell Lung Cancer. Clinical Lung Cancer. ELSEVIER. 2008;9(2): https://www.sciencedirect.com/science/article/pii/S1525730411702522?via%3Dihub. Accessed October 19, 2017. | ||
| - | Bo Li, Hai Wang, Guixing Qiu, Xinlin Su, and Zhihong Wu, “Synergistic Effects of Vascular Endothelial Growth Factor on Bone Morphogenetic Proteins Induced Bone Formation In Vivo: Influencing Factors and Future Research Directions,” BioMed Research International, vol. 2016,11 pages, https://www.hindawi.com/journals/bmri/2016/2869572/ Accessed October 19, 2017. | ||
| - | Peng H, Wright V, Usas A, et al. Synergistic enhancement of bone formation and healing by stem cell–expressed VEGF and bone morphogenetic protein-4. The Journal of Clinical Investigation. 2002;110(6):751-759. doi:10.1172/JCI15153. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC151123/ Accessed November 19, 2017. | ||
| - | Feng L, Wu H, E L, Wang D, Feng F, Dong Y, Liu H, Wang L. Effects of Vascular Endothelial Growth Factor 165 on Bone Tissue Engineering. PLoS One. 2013; 8(12): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869747/ . Accessed October 19, 2017. | ||
| - | D J Stewart, J D Hilton, J M O Arnold, J Gregoire, A Rivard, S L Archer, F Charbonneau, E Cohen, M Curtis, C E Buller, F O Mendelsohn, N Dib, P Page, J Ducas, S Plante, J Sullivan, J Macko, C Rasmussen, P D Kessler & H S Rasmussen. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 versus maximum medical treatment. Gene Ther. 2006;13:1503–1511. https://www.nature.com/articles/3302802#abstract. Accessed November 19, 2017. | ||
| - | P Kaul, CD Naylor, PW Armstrong, DB Mark, P theroux, GR dagenais. Assessment of activity status and survival according to the Canadian Cardiovascular society angina classification. Can J Cardiol 2009;25(7). http://www.sciencedirect.com/science/article/pii/S0828282X09705069. Accessed November 19, 2017. | ||
Revision as of 20:16, 20 February 2018
| This Sandbox is Reserved from January through July 31, 2018 for use in the course HLSC322: Principles of Genetics and Genomics taught by Genevieve Houston-Ludlam at the University of Maryland, College Park, USA. This reservation includes Sandbox Reserved 1311 through Sandbox Reserved 1430. |
To get started:
More help: Help:Editing |
Vascular Endothelial Growth Factor (VGEF)
| |||||||||||
References
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
